Purinergic P2Y Receptor Antagonists
"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
| Descriptor ID |
D058921
|
| MeSH Number(s) |
D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
|
| Concept/Terms |
Purinergic P2Y12 Receptor Antagonists- Purinergic P2Y12 Receptor Antagonists
- P2Y12 Receptor Antagonists
- Antagonists, P2Y12 Receptor
- Receptor Antagonists, P2Y12
- P2Y12 Purinoceptor Antagonists
- Antagonists, P2Y12 Purinoceptor
- Purinoceptor Antagonists, P2Y12
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in this website by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 38 | 19 | 57 |
| 2018 | 28 | 12 | 40 |
| 2019 | 10 | 8 | 18 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.
-
Control of Macrophage Inflammation by P2Y Purinergic Receptors. Cells. 2021 05 04; 10(5).
-
Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. Am Heart J. 2021 02; 232:84-93.
-
Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition. J Thromb Thrombolysis. 2020 Jul; 50(1):135-143.
-
Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All? N Engl J Med. 2019 10 17; 381(16):1582-1585.
-
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 10 01; 5(4):200-206.
-
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2019 12 03; 140(23):1921-1932.
-
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. Circulation. 2019 12 03; 140(23):1960-1963.
-
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
-
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019 08 14; 40(31):2595-2604.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.